- STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and moreNovartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx BioSTAT · 21d ago↗ source
- The race for an Ebola therapy beginsMale marathoners "hit the wall," mental health in 2026, and more Morning Rounds newsSTAT · 21d ago↗ source
- Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platformNovartis said Monday it will be spending $1.1 billion upfront to buy Myricx Bio, which has an antibody-drug conjugate payload platform that could offer an edge over current approaches. The Swiss…Endpoints · 21d ago